This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTRP NextTrip (NTRP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsShort InterestTrendsBuy This Stock About NextTrip Stock (NASDAQ:NTRP) 30 days 90 days 365 days Advanced Chart Get NextTrip alerts:Sign Up Key Stats Today's Range$3.50▼$3.6850-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume5,445 shsAverage Volume51,421 shsMarket Capitalization$27.92 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York. Read More NextTrip Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreNTRP MarketRank™: NextTrip scored higher than 33% of companies evaluated by MarketBeat, and ranked 222nd out of 292 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingNextTrip has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNextTrip has received no research coverage in the past 90 days.Read more about NextTrip's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NextTrip are expected to grow in the coming year, from ($0.78) to $0.12 per share.Price to Book Value per Share RatioNextTrip has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.35% of the float of NextTrip has been sold short.Short Interest Ratio / Days to CoverNextTrip has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextTrip has recently increased by 20.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNextTrip does not currently pay a dividend.Dividend GrowthNextTrip does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.35% of the float of NextTrip has been sold short.Short Interest Ratio / Days to CoverNextTrip has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextTrip has recently increased by 20.52%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NextTrip this week, compared to 0 articles on an average week.Search Interest1 people have searched for NTRP on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NextTrip insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of NextTrip is held by insiders.Percentage Held by InstitutionsOnly 3.81% of the stock of NextTrip is held by institutions.Read more about NextTrip's insider trading history. Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextTrip and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRP Stock News HeadlinesH.C. Wainwright raises Neurotrope stock target to $5February 11, 2025 | msn.comNextTrip (NASDAQ:NTRP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 2 at 2:00 AM | Paradigm Press (Ad)NextTrip, Inc.: NextTrip Introduces Group Booking Technology Platform to Streamline and Simplify Travel for GroupsAugust 1, 2024 | finanznachrichten.deNextTrip, Inc. (NTRP) Stock Price, News, Quote & History - Yahoo FinanceMay 18, 2024 | finance.yahoo.comNextTrip, Inc. (NTRP) Latest Stock News & Headlines - Yahoo FinanceApril 30, 2024 | finance.yahoo.comNextTrip Inc NTRPApril 4, 2024 | morningstar.comMAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightAugust 17, 2023 | finance.yahoo.comSee More Headlines NTRP Stock Analysis - Frequently Asked Questions How were NextTrip's earnings last quarter? NextTrip, Inc. (NASDAQ:NTRP) announced its quarterly earnings data on Tuesday, January, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01. NextTrip had a negative net margin of 2,015.64% and a negative trailing twelve-month return on equity of 580.52%. What other stocks do shareholders of NextTrip own? Based on aggregate information from My MarketBeat watchlists, some other companies that NextTrip investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE). Company Calendar Last Earnings1/14/2025Today7/02/2025Fiscal Year End2/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry LEISURE&REC SVS Sub-IndustryN/A Current SymbolNASDAQ:NTRP CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+37.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.12 million Net Margins-2,015.64% Pretax Margin-2,020.16% Return on Equity-580.52% Return on Assets-165.33% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.96 Sales & Book Value Annual Sales$500 thousand Price / Sales55.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.16 per share Price / Book0.88Miscellaneous Outstanding Shares7,650,000Free Float6,919,000Market Cap$27.92 million OptionableNo Data Beta1.54 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:NTRP) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextTrip, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextTrip With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.